



# ADDEX Pharmaceuticals



***Dr. Vincent Mutel***  
***CEO & Head of R&D***  
***ADDEX Pharmaceuticals SA***  
***www.addexpharma.com***

***Vincent.mutel@addexpharma.com***  
***12, Chemin des Aulx***  
***1228 Plan les Ouates***  
***Switzerland***  
***Tel: +41228841555***  
***Fax: +41228841556***



# COMPANY PROFILE



- ⇒ Develops therapeutics for the treatment of Central Nervous System (CNS) disorders
- ⇒ Focus on novel targets and has proprietary compounds in preclinical and clinical development for the treatment of large CNS indications including Alzheimer's disease, schizophrenia, anxiety, depression, pain and Parkinson's disease
- ⇒ Currently developing a new class of drugs that exert a modulatory activity on specific CNS targets. These modulators offer greater selectivity, superior drug-ability and in-built safety.



# FIRST CHOICE TOPIC FOR 4th CALL

## LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH



**Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches**

⇒ **LSH-2005-1.2.1-1: Marker profiling as a new tool for predictive toxicology**  
*Integrated Project (IP)*

**Studying the brain and combating diseases of the nervous system**

⇒ **LSH-2005-2.1.3-7: Characterisation and use of animal models for neurological and psychiatric diseases**  
*STREP dedicated to SMEs*

⇒ **LSH-2005-2.1.3-8: Early markers and new targets for neurodegenerative diseases**  
*STREP dedicated to SMEs*

**Term commitment:** medium (1 – 3 years)

**Expected result:** Develop further specific know-how and techniques for the allosteric modulation

**Former participation in a FP6 Project:** NO